Geographic atrophy has no cure, but certain eye injections can slow the growth of damaged areas in the retina. Two medicines approved by the U.S. Food and Drug Administration (FDA) for this condition are pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay). Other parts of care include regular eye examinations, monitoring changes in vision, and using low-vision aids to make everyday activities easier.
What Are the Main Treatment Options for Geographic Atrophy?
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD). It causes areas of light-sensitive cells in the retina to break down gradually. As these damaged areas grow, a person may experience increasing difficulty with reading, recognizing faces, or seeing details.
For many years, treatment focused mainly on monitoring the condition and helping people manage changes in their vision. The introduction of complement-inhibiting medicines has provided another option for some patients.
According to Mayo Clinic, the FDA has approved two medicines for geographic atrophy: pegcetacoplan and avacincaptad pegol. These medicines act on proteins involved in the complement system, part of the body's immune defense system that may contribute to retinal damage.
The main treatment approaches include:
- Complement inhibitor injections: Medicines that slow the enlargement of geographic atrophy lesions.
- Regular retinal monitoring: Eye examinations and imaging tests to follow changes in the affected areas.
- AREDS2 supplements when appropriate: A vitamin and mineral formula that may help certain people with age-related macular degeneration.
- Low-vision rehabilitation: Special devices, improved lighting, and practical support to maintain independence.
Which Injections Are Used to Treat Geographic Atrophy?
Both approved medicines are administered through an intravitreal injection. This means a healthcare professional gives the medicine directly into the vitreous, the gel-like substance inside the eye.
Although both medicines target the complement system, they act on different proteins and have different recommended injection schedules.
1. Pegcetacoplan (Syfovre)
Pegcetacoplan is sold under the brand name Syfovre. It is a complement inhibitor that blocks a protein called C3 and its active form, C3b. These proteins are involved in the complement pathway, which plays a role in the body's immune response.
By regulating this pathway, pegcetacoplan aims to slow the growth of areas affected by geographic atrophy.
According to the U.S. National Library of Medicine's DailyMed prescribing information for Syfovre, the recommended dose is 15 mg, given as an injection into each affected eye once every 25 to 60 days.
The treatment schedule is determined by the eye specialist. Some patients may receive injections approximately monthly, while others may receive them at longer intervals within the recommended schedule.
2. Avacincaptad Pegol (Izervay)
Avacincaptad pegol is sold under the brand name Izervay. It is another complement inhibitor used to slow the progression of geographic atrophy secondary to age-related macular degeneration.
Unlike pegcetacoplan, which targets C3, avacincaptad pegol blocks a complement protein called C5. This action helps reduce activity further along the complement pathway.
The DailyMed prescribing information for Izervay recommends a 2 mg intravitreal injection in each affected eye once monthly, approximately every 28 days.
Regular appointments are important because this treatment requires repeated injections and ongoing monitoring.
Syfovre vs. Izervay: What Is the Difference?
Both medicines are designed to slow geographic atrophy progression, but they target different parts of the complement system.
| Feature | Syfovre | Izervay |
|---|---|---|
| Generic name | Pegcetacoplan | Avacincaptad pegol |
| Target protein | C3 and C3b | C5 |
| Medicine type | Complement inhibitor | Complement inhibitor |
| Recommended injection schedule | Every 25 to 60 days | Once monthly |
| Administration | Injection into the eye | Injection into the eye |
| Main treatment goal | Slow the growth of geographic atrophy | Slow the growth of geographic atrophy |
Neither medicine has been shown to reverse existing retinal damage. The choice between them depends on factors such as the patient's eye health, treatment goals, possible risks, injection schedule, and the retina specialist's assessment.
How Effective Are Geographic Atrophy Injections?
The main benefit of complement inhibitor injections is that they can slow the enlargement of areas affected by geographic atrophy. This may help delay further retinal damage.
However, it is important to understand what these treatments can and cannot achieve.
They slow disease progression rather than restore lost vision. Geographic atrophy destroys retinal cells that are important for sight. Current injections do not replace these damaged cells or repair areas where retinal tissue has already been lost.
The American Academy of Ophthalmology's guidance on Syfovre and Izervay explains that clinical trials have shown these medicines can slow the progression of geographic atrophy, but have not demonstrated a corresponding improvement in vision.
This means that someone receiving injections may still experience changes in their eyesight. The potential benefit is slowing the growth of damaged areas rather than making existing blind or blurry spots disappear.
What Are the Possible Side Effects of Geographic Atrophy Injections?
Like other treatments given directly into the eye, complement inhibitor injections have potential side effects. Some are temporary, while others can be more serious and require prompt medical attention.
Commonly reported eye-related effects
Depending on the medicine, possible side effects include:
- Eye discomfort or pain.
- Redness or bleeding on the white part of the eye.
- Floaters, which may appear as small dark spots or moving shapes.
- Blurred vision.
- Temporary increases in pressure inside the eye.
More serious risks
Important complications associated with these injections include:
- Endophthalmitis: A serious infection inside the eye that can threaten vision.
- Retinal detachment: Separation of the retina from the tissue supporting it.
- Neovascular or wet AMD: The development of abnormal blood vessels beneath or within the retina.
- Eye inflammation: Inflammation inside the eye that may affect vision.
Pegcetacoplan also carries an important warning about retinal vasculitis and retinal vascular occlusion. These complications involve inflammation or blockage of blood vessels in the retina and may cause severe vision loss. The prescribing information reports that they can occur even after the first injection.
People receiving these medicines should promptly contact an ophthalmologist if they develop eye pain, redness, sensitivity to light, flashing lights, new blurred vision, or any sudden change in eyesight after an injection.
The Syfovre prescribing information and Izervay prescribing information describe these complications and the need for ongoing monitoring.
Before starting treatment, patients should discuss the expected benefits, possible complications, and injection schedule with their retina specialist.
Can AREDS2 Vitamins Treat Geographic Atrophy?
AREDS2 is a specially formulated combination of vitamins and minerals studied for age-related macular degeneration. It contains vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper.
These supplements may help certain people with AMD, but they do not cure geographic atrophy or replace the injections used to slow its progression.
The National Eye Institute (NEI) explains that AREDS and AREDS2 formulas benefited people with intermediate or late AMD, while no benefit was found for people with early AMD or those without AMD.
Whether supplements are appropriate depends on the stage and pattern of AMD. A retina specialist can help determine whether the AREDS2 formula is suitable and whether it should be taken alongside other treatments.
Taking ordinary multivitamins or additional high-dose supplements without guidance is not a substitute for an appropriate AMD care plan.
What Other Treatments Help People With Geographic Atrophy?
Although injections may slow retinal damage, additional care can help people manage existing vision changes and remain as independent as possible.
Regular eye examinations and retinal imaging
Ongoing examinations help an eye specialist monitor the size and location of affected retinal areas. Tests such as optical coherence tomography (OCT) and fundus autofluorescence can help identify changes over time.
Monitoring is also important because some people with geographic atrophy may develop wet AMD. If abnormal blood vessel growth occurs, the eye specialist may recommend a separate treatment approach, such as anti-VEGF injections.
Low-vision rehabilitation
Low-vision services help people make better use of their remaining eyesight. They do not reverse retinal damage, but they can make everyday tasks more manageable.
Depending on individual needs, helpful options include:
- Magnifying glasses and electronic magnifiers.
- Reading devices with enlarged text.
- Brighter lighting for reading and household activities.
- High-contrast labels and larger print.
- Specialized glasses for particular visual tasks.
- Training in techniques that improve mobility and everyday independence.
The American Society of Retina Specialists describes low-vision rehabilitation as an important supportive option for people with geographic atrophy. These services can help with reading, recognizing faces, and moving around more safely.
Healthy lifestyle habits
Healthy lifestyle choices are useful as part of overall eye care, although they cannot reverse existing geographic atrophy.
People with AMD may be encouraged to follow a balanced diet containing fruits and vegetables, avoid smoking, and discuss other health concerns with their healthcare professionals. A Mediterranean-style dietary pattern has been associated with a lower risk of geographic atrophy progression, although this does not establish that diet alone can prevent or treat the condition.
How Do Doctors Decide Whether Geographic Atrophy Injections Are Appropriate?
Not everyone with geographic atrophy necessarily needs or chooses injection treatment. A retina specialist considers the findings from an eye examination and retinal imaging before discussing available options.
Factors that may influence the decision include:
- Location of retinal damage: Whether the affected area involves the fovea, the central part of the retina responsible for sharp vision.
- Changes over time: Whether the affected areas are enlarging on follow-up scans.
- Current visual function: How the condition affects reading, driving, and other daily activities.
- Potential treatment risks: The patient's eye health and the possible complications of repeated injections.
- Practical considerations: The ability to attend regular appointments and continue the recommended injection schedule.
Patients can ask their retina specialist how much slowing of disease progression might reasonably be expected, how frequently injections would be needed, and what monitoring would be required.
Are New Treatments for Geographic Atrophy Being Developed?
Researchers are continuing to investigate additional approaches for geographic atrophy. These include gene-based treatments and other therapies intended to protect retinal cells or slow the development of atrophy.
Clinical trials are important because current approved injections do not restore retinal tissue that has already been lost. New treatments are being studied to determine whether they can provide additional benefits or offer options for people who are not suitable for existing medicines.
However, treatments being investigated in clinical trials should not be considered established treatment options until their safety and effectiveness have been demonstrated and the appropriate regulatory approvals have been granted.
Availability also varies between countries. FDA approval of Syfovre and Izervay applies to the United States; patients elsewhere should check local regulatory approval and availability with an eye specialist.
What Is the Outlook for People Receiving Geographic Atrophy Treatment?
The outlook depends on the amount of retinal damage, its location, and how the condition changes over time. Geographic atrophy can progress gradually, and its effect on daily life varies depending on whether the central area of the retina is affected.
Complement inhibitor injections offer an option for slowing the enlargement of affected areas, but they do not stop the condition completely or guarantee that vision will remain unchanged.
Regular retinal examinations, appropriate treatment discussions, and low-vision support can help people make informed decisions and manage changes in their eyesight. The aim is to preserve as much visual function as possible while supporting independence and quality of life.